Company news

Cognition Therapeutics, Inc. news in 2023

Cognition Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip Scheltens

November 15, 2023

Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer’s and Parkinson’s Diseases

November 14, 2023

Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

November 6, 2023

Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD

October 26, 2023

Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD

October 23, 2023

Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications

October 15, 2023

Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD

September 6, 2023

Cognition Therapeutics Announces Participation in Upcoming September Conferences

August 29, 2023

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 7, 2023

Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023

August 1, 2023

Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD

July 10, 2023

Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer’s Disease

July 4, 2023

Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

June 27, 2023

Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023

June 26, 2023

Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches

June 19, 2023

Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders Conferences

June 1, 2023

Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC

May 22, 2023

Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease

May 17, 2023

Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

April 30, 2023

Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023

April 18, 2023

Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative Diseases

April 11, 2023

Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer’s Disease Processes

March 27, 2023

Cognition Therapeutics Announces New Episode of “Conversations” Podcast: Insights for the Primary Care Physician: Recognizing Dementia with Lewy Bodies

March 26, 2023

Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business Update

March 22, 2023

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results

March 15, 2023

Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD

March 14, 2023

Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease

February 21, 2023

Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

February 8, 2023

Calls in 2023

Decks in 2023